Raw Pharmaceutical Grade Material Rapamycin Powder CAS 53123-88-9 with High Purity

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Solid
• Purity: >98%
• Model NO.: Rapamycin
• Product Name: Rapamycin
• CAS No.: 53123-88-9
• Molecular Formula: C51h79no13
• Molecular Weight: 914.19
• Melting Point: 183-185°c
• Boiling Point: 799.83°c (Rough Estimate)
• Density: 1.0352 (Rough Estimate)
• Transport Package: Foil Bag
• Specification: 1kg /bag
• Trademark: SENWAYER
• Origin: China
• HS Code: 29349990
• Production Capacity: 1000kg/Month

Product Description

 Raw Pharmaceutical Grade Material Rapamycin Powder CAS 53123-88-9 with High Purity

Product name	Rapamycin
CAS number	53123-88-9
Molecular formula	C51H79NO13
Molecular weight	914.19

Appearance	White Powder
Purity	99.0%
Description	Sirolimus, also known as rapamycin, is a macrolide produced by the bacteria Streptomyces hygroscopicus. It has immunosuppressant functions in humans and is used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. It prevents activation of T cells and B cells by inhibiting their response to interleukin-2 (IL-2). Sirolimus is also used as a coronary stent coating. Sirolimus works, in part, by eliminating old and abnormal white blood cells. Sirolimus is effective in mice with autoimmunity and in children with a rare condition called autoimmune lymphoproliferative syndrome (ALPS).  A growing body of evidence has demonstrated that although limited, rapamycin or rapalogs are beneficial for treating various diseases including cancer, diabetes, tuberous sclerosis complex, lymphangioleiomyomatosis, neurodegenerative diseases and aging.
Function	Rapamycin is a triene macrolide antibiotic, which demonstrates anti-fungal, anti-inflammatory, anti-tumor and immunosuppressive properties. Rapamycin has been shown to block T-cell activation and proliferation, as well as, the activation of p70 S6 kinase and exhibits strong binding to FK-506 binding proteins. Rapamycin also inhibits the activity of the protein, mTOR, (mammalian target of rapamycin) which functions in a signaling pathway to promote tumor growth. Rapamycin binds to a receptor protein (FKBP12) and the rapamycin/FKB12 complex then binds to mTOR and prevents interaction of mTOR with target proteins in this signaling pathway.

 

 

1) And sensitive mast cell membrane outside of the calcium channel, preventing calcium influx, inhibition of mast cell degranulation, reducing the release of histamine, slow reactant, leukotrienes and other inflammatory mediators, the role ofspecies selectivity and organ most sensitive to human lung mast cells.
2) Inhibition of sensory nerve endings to release substance P, neurokinin A and B induced tracheal smooth muscle spasm and mucosal edema.
3) Reducing the sensitivity of people with asthma for non-specific stimuli, reducing the attack of bronchospasm.